Resectable pancreatic cancer: The role for neoadjuvant/preoperative therapy  by Evans, Douglas B.
REVIEW ARTICLE
Resectable pancreatic cancer: The role for neoadjuvant/preoperative
therapy
DOUGLAS B. EVANS for the Multidisciplinary Pancreatic Cancer Study Group
Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Key Words: Pancreatic cancer, neoadjuvant therapy, preoperative therapy, pancreatic surgery, whipple procedure
Importance of pretreatment staging to define the
extent of disease as a necessary component of
the conduct of clinical trials and outcome
reporting
Evaluation of the potential value of nonsurgical
therapies (chemotherapy and radiation therapy) in
improving local disease control and survival of
patients with pancreatic cancer requires accurate
pretreatment staging (to define the study population)
and a standardized system for the pathologic evalua-
tion of surgical specimens (to determine the comple-
teness of resection). This is routinely performed in
most other solid tumors yet rarely completed in an
organized fashion in pancreatic cancer, making the
interpretation of the published literature difficult or
impossible. For example, the definition of resectable
pancreatic cancer used in most studies is based upon
whether or not the surgeon has removed the pancrea-
tic head, often with no system of margin analysis.
Multidetector (multislice) computed tomography
(CT) is used to objectively define (anatomically)
potentially resectable disease, borderline resectable
disease, locally advanced disease, and metastatic
disease. Although contrast-enhanced CT is widely
available, accurate interpretation and reporting of the
tumor-related findings remains inconsistent. For op-
timal pretreatment staging and assessment of oper-
ability, a CT report in a patient with suspected
periampullary or pancreatic cancer should include
the following information: (1) commentary on the
presence or absence of a primary tumor in the
pancreas; (2) commentary on the presence or absence
of peritoneal and hepatic metastases; (3) description
of the patency of the superior mesenteric vein-portal
vein confluence and the relationship of these veins to
the tumor; (4) description of the relationship of the
tumor to the superior mesenteric artery (SMA), celiac
axis, and hepatic artery.
Specific, objective radiographic criteria can be used
to create the following definitions:
Potentially resectable disease : (1) no extrapancreatic
disease, (2) a patent superior mesenteric (SMV)-
portal vein (PV) confluence (assuming the technical
ability to resect and reconstruct this venous conflu-
ence), and (3) a definable tissue plane between the
tumor and regional arterial structures including the
celiac axis, common hepatic artery, and SMA.
Borderline resectable disease : (1) no extrapancreatic
disease, (2) the following possible tumor-vessel rela-
tionships: an SMV-PV confluence that can be recon-
structed even if short segment venous occlusion is
present (i.e. a suitable portal vein above, and a
suitable SMV below the area of occlusion); tumor
abutment of the SMA of 5/1808; or short segment
encasement of the hepatic artery amenable to resec-
tion and reconstruction (this is usually at the origin of
the gastroduodenal artery and reconstruction may or
may not require interposition grafting with a short
segment of reversed saphenous vein).
Locally advanced disease : (1) no extrapancreatic dis-
ease, (2) tumor encasement of the SMA or celiac axis
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defined as tumor involvement of /1808 of the arterial
circumference.
Metastatic disease : radiographic or clinical evidence of
distant organ or peritoneal metastases.
Despite clear evidence that high-quality cross-sec-
tional imaging predicts resectability accurately, many
patients undergo laparotomy for pancreatic cancer
without adequate preoperative assessment. Some
patients are found to have unresectable tumors
intraoperatively when such a conclusion might have
been possible prior to surgery. Conversely, because of
a lack of adequate preoperative imaging and surgical
expertise, many patients who are resected with
‘curative intent’ have been left with gross residual
disease not recognized by the surgeon intraopera-
tively, or documented in the operative note.
Pathologic assessment of the surgical specimen
The modifications to the TNM staging system in the
6th edition of the AJCC Cancer Staging Manual allow
the accurate staging of patients even if they do not
undergo pancreatic resection. The T4 (and stage III)
designation is reserved for locally advanced unresect-
able primary tumors in the absence of distant
metastases. In addition to TNM staging, when the
pancreaticoduodenectomy (PD) specimen is evalu-
ated pathologically, the retroperitoneal or SMA mar-
gin (the soft tissue margin directly adjacent to the
proximal 34 cm of the SMA) must be evaluated on
permanent sections by inking the margin and section-
ing the tumor perpendicular to the margin. All
pancreatic resections should be classified according
to residual disease status (termed ‘R’ factor): R0, no
gross or microscopic residual disease; R1, microscopic
residual disease (microscopically positive surgical
margin with no gross residual disease); and R2,
grossly evident residual disease. The pathologist
cannot usually differentiate an R1 (microscopically
positive) from an R2 (grossly positive) SMA margin in
the absence of information regarding the retroperito-
neal dissection, which should be included in the
operative note. The R designation should always be
listed in the dictated operative report (we do not sign
off on the operative note until the pathology report is
available for review). For example, if the surgeon
states that gross tumor was encountered when com-
pleting the retroperitoneal dissection, a positive his-
tologic margin should result in the R2 designation in
the operative report and the medical record. In the
absence of this information being included in the
operative report, the proper R designation cannot be
determined. The difficulty in differentiating R1 from
R2 resections has significant implications for the
conduct of clinical trials examining the potential
advantage of nonsurgical therapies, especially in
patients with borderline resectable tumors.
Adjuvant therapy
Postoperative adjuvant therapy for resectable pancreatic
cancer
Pancreatic cancer is a systemic disease in most
patients at the time of diagnosis. Following a poten-
tially curative PD, disease recurs in 8090% of
patients, demonstrating that surgery alone is not an
adequate treatment for the majority of patients with
localized, resectable pancreatic cancer. While the
optimal choice of adjuvant chemotherapy vs chemor-
adiation remains controversial, recent studies do
suggest a modest survival benefit for those patients
who receive adjuvant therapy. The delivery of post-
operative adjuvant therapy often assumes that all
patients who undergo PD receive intended postopera-
tive therapy and that all patients also have all gross
tumor removed. However, at least 2530% of pa-
tients who undergo a curative resection do not receive
postoperative therapy for reasons that are disease-
related (early tumor progression), treatment-related
(such as delayed recovery from surgery), or patient-
related (medical co-morbidities, patient refusal). The
number of patients who undergo surgery but have
tumor left behind is not known due to inadequate
preoperative imaging, a lack of surgical quality con-
trol, and a failure to accurately report (pathologic)
margins of resection; incomplete resections are prob-
ably more common than we think. This is an
important point in data analysis. For example, recent
publications of single-institution experiences suggest
that local failure rates are lower when either post-
operative or preoperative radiation is delivered. This is
in contrast to a recent report from a large multi-
institutional clinical trial. However, the inability of
almost all investigators to assess the completeness of
resection following PD suggests that the retroperito-
neal margin is undoubtedly often positive, and when
negative, is usually measured in millimeters  very
similar to the situation with the radial margin in rectal
cancer. Clearly, as the quality of preoperative imaging
and surgery improves, the value of adjuvant therapies
(designed to reduce local recurrence) will decrease.
Efforts to reduce local failure rates have been well
studied in rectal cancer, where external beam radia-
tion therapy has been proven to decrease the risk of
local recurrence. Since it is hard to ensure or validate
that a negative surgical margin has been achieved in
patients who undergo PD, one may want to exercise
caution in eliminating radiation therapy from the
treatment of operable pancreatic cancer at this time.
Preoperative therapy for resectable pancreatic cancer
There are many practical and theoretical advantages
to preoperative treatment of patients with localized
pancreatic cancer. Most compelling is the ability to
provide immediate systemic therapy for a disease that
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is systemic at diagnosis in virtually all patients. A
second more practical advantage is improved patient
selection for pancreatic surgery  an operation
associated with significant patient morbidity even
when performed by experienced clinicians. This
improved patient selection arises because patients
with rapidly progressive systemic disease are identified
as part of the restaging evaluation performed follow-
ing neoadjuvant treatment prior to planned surgery.
In prospective trials, approximately 25% of patients
who begin a treatment program of preoperative
treatment do not undergo successful resection of their
primary tumor as a consequence of disease progres-
sion or evolution of clinically significant medical co-
morbidity. These patients are spared the morbidity
and prolonged recovery sometimes associated with
PD. In a series of trials performed at our institution,
patients who demonstrated disease progression after
preoperative chemoradiation had a median survival of
only 79 months. Thus, many institutions have begun
to investigate the role of chemoradiation given pre-
operatively.
Since 1988, four prospective preoperative trials
have been completed at our institution. These trials,
performed in sequence, have had identical eligibility
criteria using a CT-based definition of resectable
disease (as previously described), a uniform surgical
technique for the performance of PD, and a standar-
dized system for pathologic evaluation of surgical
specimens including resection margins. This has
maximized the number of variables held constant
while varying only the chemoradiation regimens. All
eligible patients were required to have biopsy-proven
adenocarcinoma of the pancreatic head.
In our initial preoperative study, 28 patients re-
ceived a course of continuous infusional 5-fluorour-
acil (5-FU; 300 mg/m2/day) in combination with
standard fractionation external beam radiation ther-
apy (EBRT; 50.4 Gy; 180 cGy/fraction for 28
fractions over 5.5 weeks). The gastrointestinal toxic
effects (nausea, vomiting, and dehydration) were
severe enough to require hospital admission in a third
of patients. Preoperative (post-chemoradiation) resta-
ging radiographic evaluation 45 weeks after com-
pleting preoperative therapy disclosed evidence of
metastatic disease in 25% of patients. Another 15%
had intraoperative evidence of metastatic disease at
laparotomy for an overall resectability rate of 60%.
Median survival for the patients who underwent PD
with curative intent was 18 months. The degree of
tumor cell kill was graded using a standardized
scoring system, and 40% of the resected specimens
had a pathologic partial response to therapy (/50%
of the tumor cells were nonviable). While the results
from this initial trial of preoperative therapy for
pancreatic cancer appeared equivalent to those seen
with postoperative therapy, the toxicity and hospita-
lization rate was discouraging. These findings led to a
change in the delivery of EBRT in all subsequent
preoperative trials performed at our institution.
A chemoradiation program delivered over 2 weeks
was designed to avoid the gastrointestinal toxicity
associated with standard fractionation chemoradia-
tion delivered over 5.5 weeks, while maintaining the
excellent local tumor control achieved with multi-
modality therapy. Chemoradiation was delivered with
18-MeV photons using a four-field technique to a
total dose of 30 Gy (3 Gy/fraction, 10 fractions over 2
weeks). Sequentially performed preoperative chemor-
adiation trials have evaluated continuous infusion 5-
FU, paclitaxel, and gemcitabine, all given as single
agents. In our study of short-course EBRT with
infusional 5-FU, 35 patients were enrolled, 27 were
taken to surgery, and 20 (57%) underwent successful
PD. Local tumor control and patient survival were
equal to the results with standard fractionation (5.5
weeks) chemoradiation. Of note, only 2 (10%) of the
20 patients who underwent resection developed local-
regional recurrence, and the median survival for all 20
resected patients was 25 months. Paclitaxel did not
provide an advantage over 5-FU-based chemoradia-
tion programs in terms of resection rate, local treat-
ment effect, or overall survival.
We then moved to gemcitabine-based chemoradia-
tion and performed a phase I study of gemcitabine in
combination with EBRT in patients with locally
advanced disease. This regimen combined 2 weeks
of EBRT with 7 weekly infusions of gemcitabine. The
maximum tolerated dose of gemcitabine using this
treatment schedule was 350 mg/m2/week, roughly
one-third the standard weekly dose. The results of
this phase I study were sufficiently encouraging to
proceed with gemcitabine-based preoperative che-
moradiation in a group of patients with potentially
resectable disease. A total of 86 patients were enrolled
in this phase II clinical trial from July 1998 to October
2001 (unpublished data). Despite a longer elapsed
time from enrollment to surgery (PD) compared with
previous trials (1112 weeks rather than 79 weeks),
74% of patients underwent successful PD (compared
with 60% with 5-FU-based chemoradiation). A
pathologic partial response (/50% of tumor cells
nonviable) was seen in just over 50% of the surgical
specimens. We have just completed a trial involving a
similar number of patients using a combination of
gemcitabine and cisplatin, followed by gemcitabine-
based chemoradiation prior to planned PD. Current/
future trials are combining targeted therapy (bevaci-
zumab, cetuximab) with gemcitabine-based chemor-
adiation.
Unfortunately, many reports of neoadjuvant ther-
apy for pancreatic cancer have included heteroge-
neous patient populations, enrolling patients with
locally advanced or marginally resectable pancreatic
cancer. Few investigators report clear anatomic defi-
nitions of locally advanced disease and many studies
incorporate intraoperative assessment of the extent of
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local tumor growth, data which are subjective and not
reproducible. In general, patients with locally ad-
vanced pancreatic cancer should not be included in
studies of preoperative therapy because their inclusion
confounds reports of resection rates, and complicates
comparisons to other studies. Therein lies the im-
portance of using accurate, reproducible, anatomic
definitions for resectability based on high-quality CT
imaging.
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